Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Jennifer A. Perry, Adam Kieżun, Peter Tonzi et al. · Proceedings of the National Academy of Sciences · 2014
Osteosarcoma is the most common primary bone tumor, yet there have been no substantial advances in treatment or survival in three decades. We examined 59 tumor/normal pairs by whole-exome, whole-genome, and RNA-sequencing. Only the TP53 gene was mutated at significant frequency across all samples. The mean nonsilent somatic mutation rate was 1.2 mutations per megabase, and there was a median of 230 somatic rearrangements per tumor. Complex chains of rearrangements and localized hypermutation were detected in almost all cases. Given the intertumor heterogeneity, the extent of genomic instability, and the difficulty in acquiring a large sample size in a rare tumor, we used several methods to identify genomic events contributing to osteosarcoma survival. Pathway analysis, a heuristic analytic algorithm, a comparative oncology approach, and an shRNA screen converged on the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway as a central vulnerability for therapeutic exploitation in osteosarcoma. Osteosarcoma cell lines are responsive to pharmacologic and genetic inhibition of the PI3K/mTOR pathway both in vitro and in vivo.
Cited by 478 works. doi:10.1073/pnas.1419260111 Open-access PDF
Authors
- Jennifer A. Perry
- Adam Kieżun
- Peter Tonzi
- Eliezer M. Van Allen
- Scott L. Carter
- Sylvan C. Baca
- Glenn S. Cowley
- Ami Siddharth Bhatt
- Esther Rheinbay
- Chandra Sekhar Pedamallu
- Elena Helman
- Amaro N Taylor-Weiner
- Aaron McKenna
- David S. DeLuca
- Michael S. Lawrence
- Lauren Ambrogio
- Carrie L. Sougnez
- Andrey Sivachenko
- Loren D. Walensky
- Nikhil Wagle
References
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
- A method and server for predicting damaging missense mutations
- Cancer statistics, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- Amplification of a gene encoding a p53-associated protein in human sarcomas
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
- Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition.
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development